Nektar Therapeutics (NKTR) Tops Q2 EPS by 11c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.59 +2.88%
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
- RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
